Readystate Asset Management LP Lowers Position in uniQure N.V. $QURE

Readystate Asset Management LP lessened its position in shares of uniQure N.V. (NASDAQ:QURE) by 20.5% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 400,989 shares of the biotechnology company’s stock after selling 103,713 shares during the quarter. Readystate Asset Management LP’s holdings in uniQure were worth $18,470,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Seven Fleet Capital Management LP acquired a new stake in shares of uniQure during the 2nd quarter valued at about $15,254. IFP Advisors Inc acquired a new position in uniQure in the 4th quarter worth about $48,000. Smartleaf Asset Management LLC purchased a new position in uniQure during the fourth quarter worth approximately $48,000. CIBC Private Wealth Group LLC purchased a new position in uniQure during the third quarter worth approximately $50,000. Finally, Ensign Peak Advisors Inc grew its holdings in uniQure by 21.7% in the fourth quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company’s stock valued at $87,000 after purchasing an additional 650 shares during the period. Institutional investors and hedge funds own 78.83% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on QURE shares. Wall Street Zen cut uniQure from a “hold” rating to a “sell” rating in a research report on Saturday. HC Wainwright increased their target price on uniQure from $50.00 to $80.00 and gave the company a “buy” rating in a research report on Monday, June 29th. William Blair assumed coverage on shares of uniQure in a research note on Wednesday, September 2nd. They issued an “outperform” rating on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of uniQure in a report on Friday, June 26th. Finally, Mizuho upped their price objective on shares of uniQure from $35.00 to $68.00 and gave the stock an “outperform” rating in a research report on Thursday, June 25th. Fourteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, uniQure currently has an average rating of “Moderate Buy” and a consensus price target of $65.00.

uniQure Stock Performance

QURE stock opened at $44.50 on Monday. uniQure N.V. has a 12-month low of $8.73 and a 12-month high of $71.50. The business’s 50-day moving average is $44.30 and its 200 day moving average is $30.41. The company has a current ratio of 10.01, a quick ratio of 10.01 and a debt-to-equity ratio of 0.15. The stock has a market cap of $3.09 billion, a price-to-earnings ratio of -11.10 and a beta of 0.94.

uniQure (NASDAQ:QURE) last announced its earnings results on Wednesday, July 29th. The biotechnology company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.40). The firm had revenue of $5.84 million for the quarter, compared to analyst estimates of $5.45 million. uniQure had a negative net margin of 1,350.73% and a negative return on equity of 111.96%. During the same period in the previous year, the company earned ($0.69) EPS. On average, sell-side analysts anticipate that uniQure N.V. will post -3.82 EPS for the current fiscal year.

Insider Transactions at uniQure

In other news, CEO Matthew C. Kapusta sold 21,082 shares of the company’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $45.16, for a total transaction of $952,063.12. Following the completion of the sale, the chief executive officer owned 519,227 shares of the company’s stock, valued at $23,448,291.32. This represents a 3.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jack Kaye sold 21,167 shares of the stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $46.44, for a total transaction of $982,995.48. Following the completion of the sale, the director owned 25,996 shares of the company’s stock, valued at $1,207,254.24. This trade represents a 44.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 385,584 shares of company stock valued at $16,737,722 over the last ninety days. Company insiders own 4.65% of the company’s stock.

uniQure Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.